(HealthDay News) — For patients with active cancer and acute symptomatic venous thromboembolism (VTE), full-dose tinzaparin does not reduce recurrent VTE compared with warfarin, according to a study ...
Objective and Design: Tinzaparin and dalteparin are low molecular weight heparins (LMWHs) with different pharmacokinetic and pharmacodynamic profiles that may lead to differences in efficacy and ...
Patients could be included if they were older than 18 years, were of either sex, if they had an ateriovenous (AV) fistula and/or permanent dialysis catheter, were undergoing chronic intermittent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback